Deklarify
Filings from SEC EDGAR · prices under licence
Company report

REGENXBIO Inc.

RGNX — Biological Products, (No Diagnostic Substances)
$7.95
Close on 15 Sept 2026
Last 12 months
-12.6%
Five years
-77.3%
History covered
5.0 yrs
Annual filings

REGENXBIO Inc.: annual revenue and profit

REGENXBIO Inc. (RGNX) reported annual revenue of $170.4m for the fiscal year ending 31 Dec 2025, from SEC filings.

REGENXBIO Inc. (RGNX) reported a net loss of $193.9m for the fiscal year ending 31 Dec 2025, from SEC filings.

Compared with a net loss of $227.1m for the fiscal year ending 31 Dec 2024.

See RGNX annual and quarterly financial statements · Browse RGNX filings on SEC EDGAR

The annual revenue and profit above are closed fiscal years. The headline revenue and net income below each use an available twelve-month window from the filings. A headline is missing when no such window can be calculated. Their values can differ.

Performance

What the price has done

REGENXBIO Inc. (RGNX) closed at $7.95 on 15 Sept 2026.

Over the last 12 months the price is down 12.6%.

Over the 5.0 yrs of history covered, it is down 77.3%.

The worst fall from a peak along the way was 88.4%.

Over the history covered, the price swung about 75.1% a year.

What the market pays for it

Derived by us
Line item
In plain words
Reading
Market capitalisation
What the whole company costs at that price.
$418.1m

How the price has moved

Derived by us
Line item
In plain words
Reading
Five-year total return
Price and dividends together, over the years covered.
-77.3%
Last 12 months
Price and dividends together over the last year.
-12.6%
Price history
How much price history this reading is built on.
5.0 yrs

What holding it has felt like

Derived by us
Line item
In plain words
Reading
Worst fall from a peak
Worst fall from a peak.
-88.4%
Very weak
Annual volatility
How much it swings in a year.
75.1%
Very weak

The headline figures, as filed

As filed
Line item
In plain words
Reading
Revenue (12 months)
Sales over the last twelve months, as filed.
$174.5m
FY2025: $170.4m, up from $83.3m in FY2024
Net income (12 months)
Profit the company reported for the period.
-$196.4m
FY2025: -$193.9m, up from -$227.1m in FY2024
Diluted EPS (12 months)
Profit per share, counting every share that could exist.
$-3.78
FY2025: $-3.76, up from $-4.59 in FY2024
Where this came from
What this page will not do
It will not tell you to buy. Every reading is a comparison against ordinary ranges on the general scale, worked out from figures on file. Nothing here is investment advice.